Gene Promoter Hypermethylation in Tumors and Plasma of Breast Cancer Patients

다국어 초록 (Multilingual Abstract)

Purpose: To measure the hypermethylation of four genes in primary tumors and paired plasma samples to determine the feasibility of gene promoter hypermethylation markers for detecting breast cancer in the plasma.Materials and Methods: DNA was extracted from the tumor tissues and peripheral blood plasma of 34 patients with invasive breast cancer, and the samples examined for aberrant hypermethylation in cyclin D2, retinoic acid receptor β (RAR β), twist and high in normal-1 (HIN-1) genes using methylation-specific PCR (MSP), and the results correlated with the clinicopathological parameters.Results: Promoter hypermethylation was detected at high frequency in the primary tumors for cyclin D2 (53%), RAR β (56%), twist (41%) and HIN-1 (77%). Thirty-threeof the 34 (97%) primary tumors displayed promoter hypermethylation in at least one of the genes examined. The corresponding plasma samples showed hyperme thylation of the same genes, although at lower frequencies (6% for cyclin D2, 16% for RAR β, 36% for twist, and 54% for HIN-1). Overall, 22 of the 33 (67%) primary tumors with hypermethylation of at least one of the four genes also had abnormally hypermethylated DNA in their matched plasma samples. No significant relationship was recognized between any of the clinical or pathological parameters (tumor size, axillary lymph node metastasis, stage, or Ki-67 labeling index) with the frequency of hypermethylated DNA in the primary tumor or plasma.Conclusion: The detection of aberrant promoter hypermethylation of cancer-related genes in the plasma may be a useful tool for the detection of breast cancer.

참고문헌 (Reference)

1 "a putative cytokine highly expressed in normalbut not cancerous mammary epithelial cells" 98 : 9796-801, 2001

2 "Tumor-derived aberrant methylationin plasma of invasive ductal breast cancer patients:clinical implications." 10 : 1811-5, 2003

3 "Tumor suppressor gene promoter hypermethylationin serum of breast cancer patients" 10 : 6189-93, 2004

4 "TP53 and breast cancer" 21 : 292-300, 2003

5 "Sensitive detection of DNA methylation" 983 : 120-30, 2003

6 "Presence of tumor DNA in plasma ofbreast cancer patients:clinicopathological correlations" 59 : 3251-6, 1999

7 "Molecular detection of genetic alterations inserum of colorectal cancer patients" 58 : 1405-7, 1998

8 "Microsatellitealterations in serum DNA of head and neck cancerpatients" 2 : 1035-7, 1996

9 "Microsatellite instabilityis uncommon in breast cancer" 5 : 839-44, 1999

10 "Microsatellite alterations in plasma DNA of small celllung cancer patients" 2 : 1033-5, 1996

11 "Loss of cyclin D2 expression in the majorityof breast cancers is associated with promoter hypermethylation" 61 : 2782-7, 2001

12 "Identification of epigenetic aberrant promoter methylationin serum DNA is useful for early detection of lung cancer" 11 : 1219-25, 2005

13 "Hypermethylation in histologically distinctclasses of breast cancer" 10 : 5998-6005, 2004

14 "Gene promoter hypermehtylationin tumors and serum of head and neck cancer patients" 60 : 892-5, 2000

15 "Detectionof aberrantly methylated hMLH1 promoter DNA in theserum of patients with microsatellite unstable colon cancer" 61 : 900-2, 2001

16 "Detection of gene promoter hypermethylation in thetumor and serum of patients with gastric carcinoma" 8 : 1761-6, 2002

17 "Detection of breast cancer cells in ductallavage fluid by methylation-specific PCR" 357 : 1335-6, 2001

18 "Detection of aberrant promoter hypermethylationof tumor suppressor genes in serum DNA fromnon-small cell lung cancer patients" 59 : 67-70, 1999

19 "Detection of aberrant p16 methylation in the plasma andserum of liver cancer patients" 59 : 71-3, 1999

20 "DNA methylation of RASSF1A, HIN-1, RAR-β, cyclin D2 and twist in in situ and invasive lobular breastcarcinoma." 107 : 970-5, 2003

21 "DNA methylation in serum of breastcancer patients:An independent prognostic marker" 63 : 7641-5, 2003

22 "DNA fragments in the blood plasma of cancerpatients:quantitations and evidence for their origin fromapoptotic and necrotic cells" 61 : 1659-65, 2001

23 "Circulating nucleic acids and proteomicsof plasma/serum:clinical utility" 1022 : 1-8, 2004

24 "A prospective study of K-ras mutations inthe plasma of pancreatic cancer patients" 4 : 271-5, 1998

25 "2002 annual report of the Korea central cancerregistry based on registered data from 139 hospitals" 36 : 103-14, 2004